STK39 and intrahepatic cholestasis: In conclusion, our study has provided compelling evidence that DCHT, as a potential PPARα agonist, can alleviate acute intrahepatic cholestasis with liver injury by reversing disordered bile acid and glutathione homeostasis, and inhibiting inflammatory cytokines, with the JNK/NF-ĸB/IL-6/STAT3 signaling cascades concurrently participating in the process (Supplementary Figure S5).